Bdaz, I don’t think it is unfair at all. If I have learned anything from investing in biotechs it is that when combining a new drug with multiple existing drugs, making the differentiation a pre-specified endpoint is almost done as a matter of due course. Why only have one shot when there could be more. 

Koo the success with 208 + rosuvastatin is why RVX filed for and received a patent on the combo.